We have been contacted by a pharmaceutical company to help recruit patients for a clinical trial being conducted in patients with Raynaud’s phenomenon secondary to scleroderma/systemic sclerosis. The study medication is a topical cream that will be applied to the hand. Participation will require travel to a clinical site. The first site is in Encinitas, California. Up to three additional sites in the Northeast and Midwestern states will be announced in the future. More information regarding the study is outlined below:
Have you been diagnosed with Raynaud’s phenomenon secondary to scleroderma/systemic sclerosis?
You may qualify to take part in a multi-center, Phase 2A trial to study an investigational topical cream that will be applied to the hand of patients with Raynaud’s phenomenon secondary to scleroderma/systemic sclerosis. Those who meet the following criteria may be eligible to participate:
- Adult subjects 18-79 years of age
- Ongoing Raynaud’s phenomenon secondary to scleroderma/systemic sclerosis as diagnosed by a regular physician or rheumatologist
- Must be willing to discontinue medications for Raynaud’s phenomenon 72 hours prior to each scheduled study assessment
- Must be willing to discontinue any current topical therapies that are being applied to the hands
- No open wounds on the hand used for the study
- Must be willing to provide blood samples
The total study will take place over approximately 24 days with three visits to the site location. Two of the visits will last approximately five hours. Participants may be reimbursed for time and travel expenses. All care associated with the study will be provided at no cost to the patient. For more information or details about this clinical trial, visit ClinicalTrials.gov or contact email@example.com.